MDY vs XBI
SPDR S&P MidCap 400 ETF Trust vs SPDR S&P Biotech ETF
- • MDY has the lower expense ratio at 0.23% vs 0.35% for XBI.
- • MDY pays a higher dividend yield (1.07%).
Side-by-side metrics
| Metric | MDY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.23% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.07% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $26.04B | $8.30B |
YTD return | 13.15% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.07 | 1.09 |
P/E ratio | 22.63 | — |
Last price | $672.37 | $133.66 |
Inception | — | — |
Issuer | State Street | State Street |
MDY top holdings
| FTI | TechnipFMC PLC | 0.88% |
| CASY | Casey's General Stores Inc | 0.85% |
| UTHR | United Therapeutics Corp | 0.80% |
| CW | Curtiss-Wright Corp | 0.79% |
| FLEX | Flex Ltd | 0.75% |
| XPO | XPO Inc | 0.71% |
| WWD | Woodward Inc | 0.67% |
| RGLD | Royal Gold Inc | 0.65% |
| USFD | US Foods Holding Corp | 0.64% |
| BURL | Burlington Stores Inc | 0.63% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About MDY
MDY (SPDR S&P MidCap 400 ETF Trust) is Tracks the S&P MidCap 400 index. Managed by State Street, the fund carries $26.0B in assets under management, an expense ratio of 0.23%, a dividend yield of 1.07%. Its largest holding is TechnipFMC PLC (FTI), which represents 0.9% of the portfolio. Real Estate is the fund's largest sector exposure at 7.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.